May 12, 2021
Amniox Awarded National Agreements with Premier, Inc. and The Resource Group for Birth Tissue Skin Grafting Products
Agreements afford more than 200,000 group purchasing organization members with scaled purchasing options for cryopreserved amniotic membrane and umbilical cord birth tissue products
Miami, FL – May 11, 2021 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that its parent company TissueTech was awarded a group purchasing agreement with Premier, Inc. and The Resource Group on April 1, 2021. As such, members of both Group Purchasing Organizations (GPOs) can take advantage of pre-negotiated terms for Amniox human birth tissue products to support regenerative healing and functional recovery in surgical, chronic wound, and musculoskeletal applications.
These agreements afford GPO members significant opportunities to address patient needs and expeditiously facilitate optimal clinical outcomes. All included amniotic membrane and umbilical cord birth tissue products are processed using the company’s proprietary CRYOTEK® cryopreservation process to retain the tissue’s structural and functional integrity.
“We are very pleased to have been awarded contracts with two of the nation’s leading GPOs,” said TissueTech President and Chief Executive Officer Amy Tseng. “We applaud both alliances for their innovation and recognize how our agreements with Premier and The Resource Group are contributing to the delivery of high quality, cost-effective patient care.”
About TissueTech, Inc.
TissueTech, Inc. is an emerging biotechnology company and leader in regenerative medicine using human birth tissue. TissueTech’s pioneering amniotic membrane and umbilical cord products are processed using its proprietary CRYOTEK® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. Today, TissueTech is breaking new ground with multiple Investigational New Drug clinical trials underway as the company pursues 351 biologics’ approval for products to treat patients’ unmet clinical needs. TissueTech is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 600,000 human implants with the company’s products and published over 380 peer-reviewed studies supporting TissueTech’s platform technology. Learn more at https://biotissue.com.
About Amniox Medical, Inc.
Amniox Medical, Inc. is a TissueTech, Inc. company. It is focused on harnessing the unique power of human birth tissue to support regenerative healing and functional recovery in surgical, chronic wound, and musculoskeletal applications. The Amniox family of cryopreserved amniotic membrane and umbilical cord products are processed using its proprietary CRYOTEK® technology to retain the birth tissue’s structural and functional integrity. Amniox is committed to facilitating optimal clinical outcomes, solving previously unmet clinical and patient needs, and positively impacting patients’ lives. Connect with Amniox on our Website, Physician Portal, Facebook, LinkedIn,Instagram, and Twitter, or through your local sales professional.